Carregant...
Screening for potent and selective anticlostridial leads among FDA-approved drugs
Clostridium difficile is a leading cause of morbidity and mortality particularly in hospital settings. In addition, treatment is very challenging due to the scarcity of effective therapeutic options. Thus, there remains an unmet need to identify new therapeutic agents capable of treating C. difficil...
Guardat en:
| Publicat a: | J Antibiot (Tokyo) |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7211121/ https://ncbi.nlm.nih.gov/pubmed/32132676 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41429-020-0288-3 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|